Impact of human leukocyte antigen molecules E, F, and G on the outcome of transplantation

Transplantation Proceedings

Volumn 46, Issue 9, 2014, Pages 2957-2965

  Pabon M A ^a   Navarro, C E ^a   Osorio, J C ^a,b   Gomez N ^a   Moreno, J P ^a   Donado, A F ^a   Perez H C ^a   Lozano, E ^a,c  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; MESSENGER RNA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-E ANTIGEN; HLA-F ANTIGENS; HLA-G ANTIGENS;

BONE MARROW TRANSPLANTATION; CASE CONTROL STUDY; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DISEASE FREE SURVIVAL; GENOTYPE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DISEASE-FREE SURVIVAL; GENETICS; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGY; METABOLISM; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE);

BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; GENOTYPE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84927585887     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2014.07.010     Document Type: Conference Paper

References (52)

1. Hofstetter AR, Sullivan LC, Lukacher A.E., et al. Diverse roles of nondiverse molecules: MHC class Ib molecules in host defense and control of autoimmunity. Curr Opin Immunol 2011; 23: 104-10.
2. Moscoso J, Serrano-Vela JI, Pacheco R., et al. HLA-G, -E and -F: allelism, function and evolution. Transpl Immunol 2006; 17: 61-4.
3. Hoare HL, Sullivan LC, Clements C.S., et al. Subtle changes in peptide conformation profoundly affect recognition of the non-classic MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors. J Mol Biol 2008; 377:1297-303.
4. Grimsley C, Kawasaki A, Gassner C., et al. Definitive high resolution typing of HLA-E allelic polymorphisms: identifying potential errors in existing allele data. Tissue Antigens 2002; 60: 206-12.
5. Pietra G, Romagnani C, Moretta L., et al. HLA-E and HLA-Eebound peptides: recognition by subsets of NK and T cells. Curr Pharm Des 2009; 15:3336-44.
6. Rodgers JR, Cook RG MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 2005; 5:459-71.
7. + suppressor T cells are back in the game. J Clin Invest 2010; 120:3432-4.
8. + suppressor T cells. J Clin Invest 2004; 114:1218-21.
9. Chen W, et al Perceiving the avidity of T cell activation can be translated into peripheral T cell regulation. Proc Natl Acad Sci U S A 2007; 104:20472-7.
10. + T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 2010; 120:3641-50.
11. Tamouza R, Rocha V, Busson M., et al. Association of HLA-E polymorphism with severe bacterial infection and early transplant-related mortality in matched unrelated bone marrow transplantation. Transplantation 2005; 80:140-4.
12. ∗0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006; 82: 1436-40.
13. Hosseini E, Schwarer AP, Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012; 11:15-21.
14. Hosseini E, Schwarer AP, Jalali A, et al The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation. Leuk Res 2013; 37:516-9.
15. Fürst D., Bindja J, Arnold R., et al. HLA-E polymorphisms in hematopoietic stem cell transplantation. J Tissue Antigens 2012; 79: 287-90.
16. Nguyen S, Beziat V, Dhedin N., et al. HLA-E upregulation on IFN-gamma activated AML blasts impairs CD94/NKG2Ae dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant 2009; 43:693-9.
17. Crew MD. Play it in E or G: utilization of HLA-E and G in xenotransplantation. Xenotransplantation 2007; 14:198-207.
18. Lilienfeld BG, Crew MD, Forte P, et al Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Xenotransplantation 2007; 14:126-34.
19. Ravindranath MH, Pham T, Ozawa M., et al. Antibodies to HLA-E may account for the nondonor-specific antieHLA class-Ia antibodies in renal and liver transplant recipients. Int Immunol 2012; 24:43-57.
20. O'Callaghan C.A., Bell JI Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998; 163:129-38.
21. Ishitani A, Sageshima N, Hatake K. The involvement of HLA -E and -F in pregnancy. J Reprod Immunol 2006; 69:101-13.
22. Braud VM, Allan DSJ, McMichael AJ. Functions of non-classic MHC and noneMHC-encoded class I molecules. Curr Opin Immunol 1999; 11:100-8.
23. Menier C, Rouas-Freiss N, Favier B., et al. Recent advances on the nonclassic major histocompatibility complex class I HLA-G molecule. Tissue Antigens 2009; 75:201-20.
24. Vauvert T, Hylenius S, Rørbye C, et al. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003; 55: 63-79.
25. Larsen M, Vauvert T. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol 2009; 70:1026-34.
26. Donadi EA, Castelli EC, Arnaiz-Villena A, et al. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 2011; 68:369-95.
27. Rebmann V, Busemann A, Lindemann M., et al. Detection of HLA-G5 secreting cells. Hum Immunol 2003; 64:1017-24.
28. LeMaoult J, Le Discorde M, Rouas-Freiss N, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003; 62:273-84.
29. Carosella E, Favier B, LeMaoult J. HLA-Gedependent suppressor cells: diverse by nature, function, and significance. Hum Immunol 2008; 69:700-7.
30. le Friec G., Laupeze B, Fardel O., et al. Soluble HLA-G inhibits human dendritic celletriggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol 2003; 64:752-61.
31. Boyson JE, Erskine R, Whitman M.C., et al. Disulfide bondemediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A 2002; 99:16180-5.
32. Shiroishi M, Kuroki K, Rasubala L., et al. Structural basis for recognition of the nonclassic MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A 2006; 103:16412-7.
33. Shiroishi M, Tsumoto K, Amano K., et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003; 100:8856-61.
34. Tan CY, Chong YS, Loganath A, et al Possible gene-gene interaction of KIR2DL4 with its cognate ligand HLA-G in modulating risk for preeclampsia. Reprod Sci 2009; 16:1135-43.
35. + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33:125-34.
36. Pistoia V, Morandi F, Wang X., et al. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 2007; 17:469-79.
37. LeMaoult J, Caumartin J, Daouya M., et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109:2040-8.
38. ∗0105N) and its distribution in the Spanish population. Immunogenetics 1997; 45:464-5.
39. Lajoie J, Jeanneau A, Faucher M.C., et al. Characterisation of five novel HLA-G alleles with coding DNA base changes. Tissue Antigens 2008; 72:502-4.
40. Gobin SJ, van Zutphen M, Woltman AM, et al Transactivation of classic and nonclassic HLA class I genes through the IFN-stimulated response element. J Immunol 1999; 163:1428-34.
41. Rousseau P, le Discorde M, Mouillot G, et al The 14 bp deletion-insertion polymorphism in the 30 UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003; 64: 1005-10.
42. Nasef A, Mathieu N, Chapel A., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84:231-7.
43. Smith M, Bittner JG, White S, et al HLA-Getreated tolerogenic dendritic cells induce tolerogenic potential by increasing expression of B7-1 (CD80) molecules. Transplant Proc 2008; 40: 1598-603.
44. Ristich V, Zhang W, Liang S., et al. Mechanisms of prolongation of allograft survival by HLA-G/ILT4emodified dendritic cells. Hum Immunol 2007; 68:264-71.
45. le Rond S., Azéma C, Krawice-Radanne I, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 2006; 176:3266-76.
46. Bahri R, Naji A, Menier C., et al. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 2009; 183:7054-62.
47. Qiua J, Terasakia PI, Miller J. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6:2152-6.
48. Racca A, Veaute C, Bailat A., et al. Expression of HLA-G and MICA mRNA in renal allograft. Transpl Immunol 2009; 21: 10-2.
49. + T lymphocytes: a potential predictor for acute renal rejection. Transpl Int 2011; 24:1103-11.
50. Bastürk B., Karakayali F, Emiroglu R., et al. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 2006; 38:571-4.
51. Zarkhin V, Talisetti A, Wozniak L., et al. Expression of soluble HLA-G identifies favorable outcomes in liver transplant recipients. Transplantation 2010; 90:1000-5.
52. ∗0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation. Transplantation 2009; 88:528-32.